GRM5 and neoplasm: The blockade of mGluR5 signaling through pharmacological inhibitors (riluzole or Fenobam, a negative allosteric modulator of mGluR5) or by genetic means resulted in a decrease in osteosarcoma cell growth, reduced tumor motility, and the upregulation of apoptosis [132].